Eltrombopag: A Thrombopoietin Receptor Agonist for Idiopathic Thrombocytopenic Purpura

2009 ◽  
Vol 25 (3) ◽  
pp. 176-182
Author(s):  
Min Zhu
Keyword(s):  
Adverse Effects ◽  
Idiopathic Thrombocytopenic Purpura ◽  
Receptor Agonist ◽  
Relevant Information ◽  
World Health ◽  
Dependent Manner ◽  
Thrombocytopenic Purpura ◽  
Safety And Efficacy ◽  
Platelet Counts ◽  
Chronic Itp

Objective: To review the pharmacology, pharmacokinetics, safety, and efficacy of eltrombopag in previously treated patients with chronic idiopathic thrombocytopenic purpura (ITP). Data Sources: Articles were identified through a search of the MEDLINE (1950–December 2008) database for English-language articles containing the key words eltrombopag, SB-497115, idiopathic thrombocytopenic purpura, and immune thrombocytopenic purpura. References from publications identified in this search were reviewed for relevant information. Unpublished data received from the manufacturer was also included in this review. Study Selection and Data Extraction: All articles identified from the data search were reviewed for relevant information. Applicable information was included in this review. Data Synthesis: Eltrombopag is a new oral thrombopoietic receptor agonist approved by the FDA in November 2008 as second-line treatment of chronic ITP. It stimulates human megakaryocyte differentiation and proliferation, leading to increased platelet production. Eltrombopag has been shown in clinical trials to increase platelet counts in a dose-dependent manner regardless of splenectomy status, baseline platelet counts, and concurrent ITP therapy. Available data show a statistically significant decrease in the incidence of any bleeding (World Health Organization Grades 1–4) and clinically significant bleeding (Grades 2–4). Common adverse effects are mild and typically do not lead to treatment discontinuation. Results from clinical studies demonstrated significant increase in platelet counts with minimal adverse effects. Conclusions: Eltrombopag treatment provides a potential new resource for clinicians to use in the pharmacotherapy of ITP. Further studies are needed to explore its long-term safety and efficacy in patients with chronic ITP. ACPE Universal Program Number: 407-000-09-054-H01-P (Pharmacists)

Safety and Efficacy of Long-Term Treatment with Oral Eltrombopag for Chronic Idiopathic Thrombocytopenic Purpura.

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 3432-3432 ◽  
Author(s):  
James B Bussel ◽  
Gregory Cheng ◽  
Mansoor N Saleh ◽  
Balkis Meddeb ◽  
Christine Bailey ◽  
...  
Keyword(s):  
Idiopathic Thrombocytopenic Purpura ◽  
Term Treatment ◽  
Thrombocytopenic Purpura ◽  
Once Daily ◽  
Safety And Efficacy ◽  
Platelet Counts ◽  
Chronic Itp ◽  
Long Term Treatment ◽  
Previously Treated

Abstract INTRODUCTION: Eltrombopag (PROMACTA®/REVOLADE®; GlaxoSmithKline, Collegeville, PA) is the first oral, small molecule, non-peptide thrombopoietin receptor agonist under investigation for the treatment of thrombocytopenia due to various causes, including idiopathic thrombocytopenic purpura (ITP). Chronic ITP is characterized by autoantibody-induced platelet destruction and reduced platelet production, leading to chronically low peripheral platelet counts. Eltrombopag treatment has previously demonstrated a significant increase in platelet counts and a reduction in clinically relevant bleeding symptoms in 2 placebo-controlled trials evaluating a total of >200 patients with chronic ITP after up to 6 weeks of treatment. EXTEND is an ongoing open-label, phase III extension study to assess the long-term safety and efficacy of oral eltrombopag in ITP patients that have previously completed an eltrombopag trial. METHODS: Patients with previously treated, chronic ITP who completed a prior eltrombopag study were eligible to participate in EXTEND. Eltrombopag treatment was initiated at 50 mg once daily and then adjusted in order to maintain platelet counts ≥ 50,000/μL and <400,000/μL, with doses between 75 mg once daily and 25 mg once daily or less often than once daily, if necessary. Patients who achieved platelet counts ≥ 50,000/μL during treatment with eltrombopag were considered responders. Bleeding events were prospectively evaluated using the WHO Bleeding Scale: Grade 0 = no bleeding, Grade 1 = mild bleeding, Grade 2 = moderate bleeding, Grade 3 = gross bleeding and Grade 4 = debilitating blood loss. RESULTS: At the time of this analysis, 207 patients (median age, 50 years; 67% female) had received eltrombopag on this study. At baseline, 33% were receiving concomitant ITP medication and 40% were splenectomized. The majority of patients (70%) enrolled with baseline platelet counts <30,000/μL, followed by 18% and 12% with baseline platelet counts from ≥ 30,000/μL to ≤ 50,000/μL, and >50,000/μL, respectively. The duration of eltrombopag treatment ranged from 3 to 523 days. Seventy-nine percent (159/201) of patients achieved a platelet count ≥ 50,000/μL, and 24% (18/75) of patients who had received eltrombopag for at least 25 weeks maintained platelet counts ≥ 50,000/μL continuously for ≥ 25 weeks. Patients responded to eltrombopag regardless of splenectomy status (non-splenectomized: 78%, splenectomized: 81%) and use of baseline concomitant ITP medications (no baseline ITP medications: 79%, baseline ITP medications: 80%). Median platelet counts remained ≥ 50,000/μL throughout the observation period of the study (Figure 1) with only 3 exceptions, when the median platelet counts remained >40,000/μL. At baseline, 59% of patients reported bleeding symptoms (WHO Grades 1–4) compared with approximately 30% at months 1, 3, and 6. Adverse events (AEs) were reported in 150 patients (72%) while on therapy, the majority of which were mild to moderate. Headache (15%) was the most commonly reported on-therapy AE, followed by upper respiratory tract infection (13%), diarrhea (10%), and nasopharyngitis (9%). Six thromboembolic events were reported during the study. No clinically relevant effects of eltrombopag on patient bone marrow were detected. Thirty-nine serious AEs were reported by 17 patients (8%) while on therapy +1 day. Four deaths were reported in the study (2 deaths on therapy and 2 deaths >30 days after the last dose of eltrombopag); none were considered related to study medication. CONCLUSION: Oral eltrombopag is effective at raising platelet counts and decreasing bleeding symptoms during long-term treatment, regardless of splenectomy status or the use of baseline ITP medications. Eltrombopag is well tolerated during long-term treatment in patients with previously treated chronic ITP. Figure 1. Median platelet counts.a
 BL, median baseline value.
 aDotted line indicates 50,000 platelets/μL. Figure 1. Median platelet counts.a
 BL, median baseline value.
 aDotted line indicates 50,000 platelets/μL.

scholarly journals Subarachnoid Haemorrhage Complicating Resistant Idiopathic Thrombocytopenic Purpura: A Case Report

2014 ◽  
Vol 4 (2) ◽  
pp. 105-107
Author(s):  
Farhana Afroz ◽  
Hasna Fahmima Haque ◽  
Samira Rahat Afroze ◽  
Muhammad Abdur Rahim ◽  
Aparna Rahman ◽  
...  
Keyword(s):  
Case Report ◽  
Autoimmune Disease ◽  
Subarachnoid Haemorrhage ◽  
Idiopathic Thrombocytopenic Purpura ◽  
Conservative Management ◽  
Thrombocytopenic Purpura ◽  
Platelet Counts ◽  
Chronic Itp

Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disease where low platelet counts predisposeto various bleeding tendencies; intracranial haemorrhageis one of them. It is a rare and devastating complication of ITP, mostly presenting as intracerebral (ICH) or subarachnoid haemorrhage (SAH). Here, we report a 32-year-old splenectomized chronic ITP patient on corticosteroid and azathioprine, in whom spontaneous SAH developed. In this case, conservative management resulted in clinicoradiological improvement and showed eventual favourable out-come.Birdem Med J 2014; 4(2): 105-107

scholarly journals Abnormal platelet function and arachidonate metabolism in chronic idiopathic thrombocytopenic purpura

Blood ◽  
1981 ◽  
Vol 58 (2) ◽  
pp. 326-329 ◽  
Author(s):  
MJ Stuart ◽  
JG Kelton ◽  
JB Allen
Keyword(s):  
Platelet Aggregation ◽  
Idiopathic Thrombocytopenic Purpura ◽  
Platelet Function ◽  
Bleeding Time ◽  
Bleeding Tendency ◽  
Chronic Idiopathic Thrombocytopenic Purpura ◽  
Thrombocytopenic Purpura ◽  
Platelet Counts ◽  
Chronic Itp ◽  
Arachidonate Metabolism

Abstract We observed several patients with chronic idiopathic thrombocytopenic purpura (ITP) whose bleeding times were more prolonged than would have been expected from their platelet counts. To investigate this further, we performed in vivo and in vitro platelet function studies, assessed arachidonate metabolism, and measured platelet-associated IgG (PAIGG) in seven patients with chronic ITP. The bleeding times of three of the patients were prolonged for greater than 7 min, and all of these patients had impaired platelet aggregation and abnormal platelet arachidonic acid metabolism as reflected by increased production of the lipoxygenase product HETE and a concomitant decrease in cyclooxygenase products, TXB2 and HHT (p less than 0.001). The abnormalities noted were not due to concomitant drug ingestion, since they were present on repeated evaluation. There was no relationship between the platelet count and the bleeding time; however, there was a significant inverse correlation between the bleeding time and TXB2 production in all patients evaluated (r = 0.81; p less than 0.05). There was no relationship between the level of platelet-associated IgG and any parameter of platelet aggregation or arachidonate metabolism. The abnormalities noted should be looked for in the individual patient with chronic ITP, since the bleeding tendency is exacerbated by the superimposed impairment of platelet function even at platelet counts of greater than 50,000/cu mm, levels generally regarded as “safe”.

Efficacy and Safety of Repeated Intermittent Treatment with Eltrombopag in Patients with Chronic Idiopathic Thrombocytopenic Purpura.

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 3431-3431 ◽  
Author(s):  
James B Bussel ◽  
Bethan Psaila ◽  
Mansoor N Saleh ◽  
Sandra Vasey ◽  
Bhabita Mayer ◽  
...  
Keyword(s):  
Treatment Group ◽  
Idiopathic Thrombocytopenic Purpura ◽  
Bleeding Events ◽  
Who Grade ◽  
Thrombocytopenic Purpura ◽  
Platelet Counts ◽  
Chronic Itp ◽  
Temporary Treatment ◽  
Clinically Significant ◽  
Grade 3

Abstract INTRODUCTION: Platelet levels may fluctuate in patients with idiopathic thrombocytopenic purpura (ITP) due to a number of factors, indicating a potential need for repeated, temporary treatment to raise platelet counts. REPEAT was a single-arm, openlabel, phase II study evaluating consistency of response and safety following repeated intermittent dosing of eltrombopag (PROMACTA®/REVOLADE®; GlaxoSmithKline, Collegeville, PA) in adults with chronic ITP. Eltrombopag is the first oral, small molecule, non-peptide thrombopoietin receptor agonist. METHODS: Eltrombopag 50 mg was administered once daily for 3 treatment cycles to patients with baseline platelet counts between 20,000 and 50,000/μL. A cycle consisted of an on-therapy period of up to 6 weeks followed by an off-therapy period of up to 4 weeks. Response was defined as platelets ≥50,000/μL and 2X baseline at Day 43 of each treatment cycle; patients who discontinued treatment before 6 weeks due to platelet counts >200,000/μL were also considered responders and continued on study. Only patients responding in Cycle 1 continued on to Cycles 2 and 3. The primary endpoint was the proportion of patients who responded to eltrombopag treatment in Cycles 2 or 3, given a response in Cycle 1. Bleeding symptoms were prospectively evaluated using the WHO Bleeding Scale: Grade 0 = no bleeding, Grade 1 = mild bleeding, Grade 2 = moderate bleeding, Grade 3 = gross bleeding, and Grade 4 = debilitating blood loss. RESULTS: Sixty-six patients were enrolled in the study: the median age was 51 years; 71% were Caucasian; 68% were female; 44% had baseline platelet counts ≥20,000 to ≤30,000/μL; 47% had baseline platelet counts >30,000 to ≤50,000/μL; 30% were splenectomized; 33% were receiving baseline ITP medication; 50% had bleeding symptoms (WHO Grades 1–4); and 19% had clinically significant bleeding symptoms (WHO Grades 2–4). Sixty-five patients were evaluable in Cycle 1: 80% (n = 52 of 65) responded in Cycle 1, with 87% (n = 45 of 52) achieving a response in Cycles 2 or 3 (95% CI, 74%–94%; Figure 1). By Days 8 and 15 of each cycle, >50% and >75% of patients had responded, respectively. Median platelet counts were similarly elevated on Days 8 and 15 across all 3 cycles (Figure 1) and remained >79,000/μL after Day 8 in each cycle. Median platelet counts remained elevated for 1 week after discontinuation and returned to near baseline after 2 weeks. Bleeding symptoms were reduced in approximately 50% of patients during each on-therapy period, with <20% of patients experiencing any bleeding at Day 43 in each cycle. The frequency of bleeding events increased during off-therapy periods compared with on-therapy periods, as platelet counts declined toward baseline. No WHO Grade 3 or 4 bleeding symptoms were reported during treatment. While platelet counts decreased and returned to baseline after cessation of eltrombopag treatment, these decreases were not accompanied by clinically meaningful increases in bleeding symptoms or the need for rescue medications. The overall incidence of adverse events (AEs) was similar across cycles, with <50% of patients experiencing an on-therapy AE during any given cycle. Headache was the most frequently reported AE (21%). One serious AE was reported during treatment with eltrombopag (Grade 2 pneumonia) and was considered unrelated to eltrombopag treatment. CONCLUSIONS: Repeated intermittent use of eltrombopag produced consistent and predictable responses in patients with chronic ITP, with a majority of patients experiencing similar increases in platelet counts and concomitant reductions in bleeding symptoms in each subsequent cycle. In addition, eltrombopag appeared to be well tolerated. Figure 1. Median platelet countsa
 On, on-therapy period; Off, off-therapy period.
 aError bars represent the 25th to 75th percentiles for each treatment group. Figure 1. Median platelet countsa
 On, on-therapy period; Off, off-therapy period.
 aError bars represent the 25th to 75th percentiles for each treatment group.

Oral Eltrombopag Treatment Reduces the Need for Concomitant Medications in Patients with Chronic Idiopathic Thrombocytopenic Purpura.

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 3424-3424 ◽  
Author(s):  
Patrick F. Fogarty ◽  
James B Bussel ◽  
Gregory Cheng ◽  
Mansoor N Saleh ◽  
Balkis Meddeb ◽  
...  
Keyword(s):  
Idiopathic Thrombocytopenic Purpura ◽  
Phase Iii ◽  
Term Therapy ◽  
Chronic Idiopathic Thrombocytopenic Purpura ◽  
Thrombocytopenic Purpura ◽  
Once Daily ◽  
Platelet Counts ◽  
Chronic Itp ◽  
Rescue Treatment

Abstract INTRODUCTION: Eltrombopag (PROMACTA®/REVOLADE®; GlaxoSmithKline, Collegeville, PA) is the first oral, small molecule, non-peptide thrombopoietin receptor agonist developed as a treatment for thrombocytopenia of various etiologies, including chronic idiopathic thrombocytopenic purpura (ITP). In 2 placebo-controlled studies totaling over 200 patients with chronic ITP, eltrombopag has demonstrated a significant increase in platelet counts and a reduction in clinically relevant bleeding after up to 6 weeks of treatment. EXTEND is an ongoing open-label, phase III extension study to assess the long-term safety and efficacy of oral eltrombopag. Although the primary objective of this study was to raise platelet counts to a safe level (≥50,000/μL), the ability of eltrombopag treatment to allow patients to reduce concomitant ITP medications and avoid the adverse events associated with those therapies was also of interest. METHODS: Adult patients with previously treated chronic ITP who completed a prior eltrombopag study were eligible to participate in EXTEND. Eltrombopag treatment was initiated at 50 mg once daily and then adjusted to maintain platelet counts ≥50,000/μL and <400,000/μL, with doses between 75 mg once daily and 25 mg once daily or less often than once daily, if necessary. The effect of eltrombopag treatment on the ability of patients to reduce and/or discontinue baseline concomitant ITP medications was evaluated. RESULTS: As of the clinical cut-off date (January 7, 2008), 207 patients (median age, 50 years; 67% female) had received eltrombopag. At baseline, 69 (33%) patients reported the use of ITP medications; of these, 65 patients had at least 1 post-baseline visit by the clinical cut-off date and were evaluable for response status. Eighty percent (52/65) of these patients responded to eltrombopag with a platelet count of ≥50,000/μL during the study. Forty-eight percent (33/69) of patients attempted to reduce or discontinue their concomitant ITP medications during the study. Seventy percent (23/33) of these patients discontinued or had a sustained reduction of their baseline ITP medication and did not require any subsequent rescue treatment as of the clinical cut-off date; of these, 65% (15/23) had maintained the discontinuation or reduction for at least 24 weeks as of the clinical cut-off date. Sixty-one percent (20/33) of patients discontinued at least 1 baseline ITP medication, and 55% (18/33) discontinued all baseline ITP medications, without subsequent rescue treatment. Discontinued or reduced medications included prednisone (n = 11); prednisolone (n = 8); danazol (n = 5); and azathioprine, dexamethasone, mycophenolic acid, and oxymetholone (n = 1 each). Only 12% (8/69) of patients increased the dose of concomitant ITP medication from baseline. CONCLUSION: In this study, long-term therapy with oral eltrombopag allowed 80% of patients with chronic ITP who were also receiving a concomitant ITP medication at baseline to maintain elevated platelet counts sufficient to permit a reduction in the use of concomitant ITP medications without the need for rescue therapy.

scholarly journals Abnormal platelet function and arachidonate metabolism in chronic idiopathic thrombocytopenic purpura

Blood ◽  
1981 ◽  
Vol 58 (2) ◽  
pp. 326-329 ◽  
Author(s):  
MJ Stuart ◽  
JG Kelton ◽  
JB Allen
Keyword(s):  
Platelet Aggregation ◽  
Idiopathic Thrombocytopenic Purpura ◽  
Platelet Function ◽  
Bleeding Time ◽  
Bleeding Tendency ◽  
Chronic Idiopathic Thrombocytopenic Purpura ◽  
Thrombocytopenic Purpura ◽  
Platelet Counts ◽  
Chronic Itp ◽  
Arachidonate Metabolism

We observed several patients with chronic idiopathic thrombocytopenic purpura (ITP) whose bleeding times were more prolonged than would have been expected from their platelet counts. To investigate this further, we performed in vivo and in vitro platelet function studies, assessed arachidonate metabolism, and measured platelet-associated IgG (PAIGG) in seven patients with chronic ITP. The bleeding times of three of the patients were prolonged for greater than 7 min, and all of these patients had impaired platelet aggregation and abnormal platelet arachidonic acid metabolism as reflected by increased production of the lipoxygenase product HETE and a concomitant decrease in cyclooxygenase products, TXB2 and HHT (p less than 0.001). The abnormalities noted were not due to concomitant drug ingestion, since they were present on repeated evaluation. There was no relationship between the platelet count and the bleeding time; however, there was a significant inverse correlation between the bleeding time and TXB2 production in all patients evaluated (r = 0.81; p less than 0.05). There was no relationship between the level of platelet-associated IgG and any parameter of platelet aggregation or arachidonate metabolism. The abnormalities noted should be looked for in the individual patient with chronic ITP, since the bleeding tendency is exacerbated by the superimposed impairment of platelet function even at platelet counts of greater than 50,000/cu mm, levels generally regarded as “safe”.

Long-Term Safety and Efficacy of Oral Eltrombopag for the Treatment of Subjects with Idiopathic Thrombocytopenic Purpura (ITP): Preliminary Data from the EXTEND Study.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 566-566 ◽  
Author(s):  
James B. Bussel ◽  
Gregory Cheng ◽  
Lidia Kovaleva ◽  
Mansoor N. Saleh ◽  
Balkis Meddeb ◽  
...  
Keyword(s):  
Adverse Event ◽  
Platelet Count ◽  
Idiopathic Thrombocytopenic Purpura ◽  
Who Grade ◽  
Thrombocytopenic Purpura ◽  
Safety And Efficacy ◽  
Platelet Counts ◽  
Stage 4 ◽  
Stage 1

Abstract Idiopathic thrombocytopenic purpura (ITP) is a disease caused by inadequate platelet production as well as increased platelet destruction. Eltrombopag is a first-in-class, oral, non-peptide platelet growth factor that increases platelet counts by interacting with the thrombopoietin receptor on megakaryocytes and their precursors. Accordingly, in two completed 6-week, randomized, double-blind, placebo-controlled studies of adult subjects with chronic ITP, eltrombopag produced a substantial dose-dependent increase in platelet counts. EXTEND is an ongoing, open-label extension study designed to assess the long-term safety and efficacy of oral eltrombopag. Subjects previously enrolled in an eltrombopag study are eligible to enroll in EXTEND after an intervening washout period of at least 4 weeks. Subjects are administered a starting dose of 50 mg/day (which could be increased to 75 mg/day at any time after 3 weeks) in order to reach a platelet count of ≥50,000/uL (stage 1). Then, concomitant ITP medications, if taken at study entry, are tapered to a minimal dose or discontinued entirely (stage 2), whilst maintaining a platelet count of ≥50,000/uL. Eltrombopag is then titrated to a minimal effective dose (25–75 mg/day) required to maintain platelet counts of 50,000/uL-200,000/uL (stage 3). Eltrombopag is continued for as long as the subject continues to benefit (stage 4). Bleeding incidence and severity is assessed using the WHO bleeding scale (Grade 0–4). As of August 6, 2007, data were available on 96 subjects. Ninety-four subjects were administered eltrombopag. Evaluable subjects (n=89) had a median treatment duration of 151 days (2–333 days). At baseline, 42 (44%) subjects had a platelet count ≤15,000/uL, 60 (63%) had evidence of bleeding (WHO Grade 1-4), 44 (46%) were splenectomized, and 35 (36%) were receiving concomitant ITP treatment. Of the sixty-one subjects who entered into the study with a platelet count <30,000/uL, 43 (73%) achieved a platelet count of ≥50,000/uL while on study; 10 of the 61 subjects had at least one count ≥400,000/mL during the study. Of the 94 subjects who received at least one dose of eltrombopag, 78 (83%) reported at least one adverse event; 30 (32%) reported a drug-related adverse event (AE). Most AEs were mild in severity with the most common being headache (20%). Twelve (13%) subjects reported a serious adverse event. Two deaths were reported (traffic accident and hypovolaemic shock), both not related to study medication. To date, these findings of the EXTEND study suggest that eltrombopag is well tolerated and sustains increased platelets counts during long-term treatment. Stage Description Subjects entering Median Platelet counts (/uL) WHO Grade 2–4 Bleeding n (%) Stage 1 eltrombopag administered 94 16,000 25 (27%) Stage 2 tapering ITP con meds 17 143,500 4 (24%) Stage 3 titrating eltrombpag to maintain platelet counts 46 108,500 3 (7%) Stage 4 treating with eltrombopag long-term 27 104,000 1 (4%)

CP-080 Thrombopoietin receptor agonist treatment in idiopathic thrombocytopenic purpura

2015 ◽  
Vol 22 (Suppl 1) ◽  
pp. A32.1-A32
Author(s):  
MH García Lagunar ◽  
I Español Morales ◽  
M Martínez Penella ◽  
I Muñoz García ◽  
M Gutiérrez Cívicos ◽  
...  
Keyword(s):  
Idiopathic Thrombocytopenic Purpura ◽  
Receptor Agonist ◽  
Thrombocytopenic Purpura ◽  
Thrombopoietin Receptor ◽  
Thrombopoietin Receptor Agonist

Clinical Study of TJ-137 Tsumura Kami-kihi-to in Patients with Idiopathic Thrombocytopenic Purpura (ITP)

1996 ◽  
Vol 2 (3) ◽  
pp. 213-218
Author(s):  
Nobuo Sakuragawa ◽  
Kojiro Yasunaga ◽  
Takeo Nomura ◽  
Junichi Akatsuka ◽  
Atsushi Kuramoto ◽  
...  
Keyword(s):  
Platelet Count ◽  
Clinical Study ◽  
Idiopathic Thrombocytopenic Purpura ◽  
Adverse Reactions ◽  
Clinical Effect ◽  
Thrombocytopenic Purpura ◽  
New Drug ◽  
Chronic Itp ◽  
Low Incidence

TJ-137 administered to patients with chronic ITP increased the platelet count "slightly" or more in 31.7% of the patients and showed a clinical effect in 40.9% with a rating of "modestly effective" or better. With a low incidence of adverse reactions, TJ-137 is ex pected to be a new drug for the treatment of ITP.

Sign in / Sign up

Export Citation Format

Share Document